Clinical Trials Logo

Pulmonary Fibrosis clinical trials

View clinical trials related to Pulmonary Fibrosis.

Filter by:

NCT ID: NCT06179342 Completed - Asthma Clinical Trials

Multiple Breath Washout as a Method for Diagnosing Lung Diseases

Start date: June 21, 2021
Phase:
Study type: Observational

Comparison of the new multiple-breath washout method (ndd Medizintechnik Zürich, Trueflow™/Truecheck™) with established methods of lung function diagnostics in patients with idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, asthma and cardiopulmonary healthy individuals.

NCT ID: NCT06162884 Not yet recruiting - Pulmonary Fibrosis Clinical Trials

Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis

IS-PPF
Start date: December 22, 2023
Phase:
Study type: Observational

This study is a prospective observational study for subjects with idiopathic pulmonary fibrosis (IPF) or non-IPF interstitial lung diseases (ILD). The purpose of this study is to compare whether imaging patterns from high-resolution computed tomography (HRCT) at baseline can predict worsening. Single Time point Prediction (STP) is a score derived from an artificial intelligenc/ machine learning (AI/ML) using the radiomic features from a HRCT scan that quantifies the imaging patterns of short-term predictive worsening.

NCT ID: NCT06160440 Completed - Pulmonary Fibrosis Clinical Trials

The Safety, Tolerability, and Pharmacokinetic Study of SC1011 in Healthy Subjects.

Start date: June 3, 2021
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to learn about the safety, tolerability and pharmacokinetic profiles of SC1011,in health conditions. The main questions it aims to answer are: Safety and tolerability profiles in healthy subjects.Pharmacokinetic profiles in healthy subjects.Food effect in healthy subjects.Participants will complete the study including screening period, dosing period, and observation period. Researchers will compare the inhibitory activity of SC1011 tablets with pirfenidone capsules against the same biomarkers(e.g. blood TNFα) to see if they are different between the two drugs.

NCT ID: NCT06135363 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Safety, Tolerability and Pharmacokinetic Study of SC1011 in Healthy Subjects

Start date: August 11, 2022
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to learn about the safety, tolerability and pharmacokinetic profiles of SC1011 in healthy conditions. The main questions it aims to answer are: Safety and tolerability profiles in healthy subjects and pharmacokinetic profiles in healthy subjects. Participants will complete the study including screening period, dosing period, and observation period. Investigators will compare the inhibitory activity of SC1011 tablets with pirfenidone capsules against the same biomarkers(e.g. blood TNFα) to see if they are different between the two drugs.

NCT ID: NCT06132256 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Start date: December 11, 2023
Phase: Phase 2
Study type: Interventional

The study will evaluate the efficacy and safety of axatilimab in participants with IPF.

NCT ID: NCT06125327 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

Start date: June 6, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this clinical trial is to evaluate the efficacy and safety of Sufenidone (SC1011) in patients with IPF, and to provide a new safe and effective treatment option for patients with IPF. Participants will complete the study including screening period, treating period, and follow-up period. Investigators will compare the annual rate of decline in FVC to see if it is an optional new drug. The participants have lung function tests at study visits. The results of the lung function tests are compared between the SC1011 groups and the placebo group. The doctors also regularly check the general health of the participants.

NCT ID: NCT06124859 Not yet recruiting - Clinical trials for Pulmonary Disease, Chronic Obstructive

Exercise Tolerance and Lower-limb Muscle Power in Patients With Chronic Respiratory Disease

VTEP
Start date: November 2023
Phase: N/A
Study type: Interventional

The aim of this study is to validate the six minute Stepper Test (6MST) and the 5-repetition chair lift test (5STS) as measures of exercise tolerance and muscle power, respectively, in patients with chronic respiratory disease. As the reproducibility of the tests has been studied and validated in previous studies, the objective is to investigate the validity of the 6MST and 5STS in comparison with their respective gold standards.

NCT ID: NCT06122233 Not yet recruiting - Pulmonary Fibrosis Clinical Trials

REBUILD-SM Study for People With Interstitial Lung Disease (ILD)

Start date: May 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare REBUILD-SM (a purpose-built smartphone app and self-management package) with standard care in people with interstitial lung disease (ILD). The main question it aims to answer is: • Does REBUILD-SM improve health-related quality of life, symptoms, anxiety, self-efficacy and physical activity for people with ILD? Participants in the intervention group will work through the self-management package with support from a healthcare professional via phone or Zoom. They will also enter deidentified health data into the RE-BUILD smartphone app to track their progress over time. Participants in the control group will use a reduced functionality version of the smartphone app only. Researchers will compare both groups to see if there is any difference in health-related quality of life, symptoms, anxiety, self-efficacy and level of physical activity.

NCT ID: NCT06102083 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis

Start date: November 2, 2023
Phase: Phase 2
Study type: Interventional

This trial was performed in patients with idiopathic pulmonary fibrosis (IPF) to evaluate the clinical efficacy and safety of different doses of TDI01 Suspension, compared with control, for the treatment of patients with IPF.

NCT ID: NCT06097260 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

Start date: November 16, 2023
Phase: Phase 2
Study type: Interventional

A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).